Literature DB >> 12409184

Quality of life in patients with multiple sclerosis: the impact of fatigue and depression.

Vallabh Janardhan1, Rohit Bakshi.   

Abstract

Quality of Life (QOL) is impaired in multiple sclerosis (MS) in part due to physical disability. MS-associated fatigue (MSF) and depression (MSD) are common and treatable features of MS, which could also impact on QOL, independent of physical disability. We prospectively studied 60 consecutive patients with MS. QOL was assessed using Multiple Sclerosis Quality of Life (MSQOL)-54. Group differences in QOL scores were assessed after adjusting for Expanded Disability Status Scale (EDSS), Fatigue Severity Scale (FSS) and Hamilton Depression Inventory scores. MS patients were grouped into relapsing-remitting (RR) or secondary-progressive (SP), MSF (FSS> or =5) or MS-nonfatigue (MSNF) (FSS< or =4), and MSD or MS-nondepression (MSND). After accounting for disability and depression, fatigue was associated with impaired QOL with respect to health perception (p=0.03) and limitations due to physical dysfunction (p=0.008). After accounting for disability and fatigue, depression was associated with lower QOL with respect to health perception (p=0.02), sexual dysfunction (p=0.03), health distress (p=0.03), mental health (p=0.006), overall QOL (p=0.006), emotional dysfunction (p=0.04), and limitations due to emotional dysfunction (p=0.03). This study demonstrates that fatigue and depression are independently associated with impaired QOL in MS, after accounting for physical disability, suggesting that their recognition and treatment can potentially improve QOL.

Entities:  

Mesh:

Year:  2002        PMID: 12409184     DOI: 10.1016/s0022-510x(02)00312-x

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  114 in total

Review 1.  Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment.

Authors:  Tiffany J Braley; Ronald D Chervin
Journal:  Sleep       Date:  2010-08       Impact factor: 5.849

2.  A novel approach to estimate the minimally important difference for the Fatigue Impact Scale in multiple sclerosis patients.

Authors:  Regina Rendas-Baum; Min Yang; Francoise Cattelin; Gene V Wallenstein; John D Fisk
Journal:  Qual Life Res       Date:  2010-07-10       Impact factor: 4.147

3.  Factors associated with health-related quality of life among older people with multiple sclerosis.

Authors:  Marijean Buhse; Wendy M Banker; Lynn M Clement
Journal:  Int J MS Care       Date:  2014

4.  Goals set after completing a teleconference-delivered program for managing multiple sclerosis fatigue.

Authors:  Miho Asano; Katharine Preissner; Rose Duffy; Maggie Meixell; Marcia Finlayson
Journal:  Am J Occup Ther       Date:  2015 May-Jun

5.  Sleepiness, fatigue, and risk of obstructive sleep apnea using the STOP-BANG questionnaire in multiple sclerosis: a pilot study.

Authors:  Robert A Dias; Kimberly A Hardin; Heather Rose; Mark A Agius; Michelle L Apperson; Steven D Brass
Journal:  Sleep Breath       Date:  2012-01-21       Impact factor: 2.816

Review 6.  Carnitine for fatigue in multiple sclerosis.

Authors:  Aaron M Tejani; Michael Wasdell; Rae Spiwak; Greg Rowell; Shabita Nathwani
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

7.  Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

Authors:  Ida S Haussleiter; Martin Brüne; Georg Juckel
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

Review 8.  Sexuality in Huntington's disease.

Authors:  Eva Z Schmidt; Raphael M Bonelli
Journal:  Wien Med Wochenschr       Date:  2008

9.  Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study.

Authors:  Jeffrey Wilken; Robert L Kane; Cynthia L Sullivan; Mark Gudesblatt; Sylvia Lucas; Robert Fallis; Xiaojun You; Pam Foulds
Journal:  Int J MS Care       Date:  2013

Review 10.  Sexuality in multiple sclerosis.

Authors:  E Z Schmidt; P Hofmann; G Niederwieser; H-P Kapfhammer; R M Bonelli
Journal:  J Neural Transm (Vienna)       Date:  2005-03-07       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.